Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833544 | 0.83 | CYP1A2 (0.44) | CYP1A2GRM5PIM1PIM2ALDH1A1 | |
| SCHEMBL15913597 | 0.78 | CYP1A2 (0.32) | CYP1A2GRM5PIM1PIM2ALDH1A1 | |
| SCHEMBL15913596 | 0.78 | CYP1A2 (0.32) | CYP1A2GRM5PIM1PIM2ALDH1A1 | |
| SCHEMBL15913592 | 0.78 | CYP1A2 (0.32) | CYP1A2GRM5PIM1PIM2ALDH1A1 | |
| SCHEMBL15913994 | 0.77 | DDB1 (0.37) | CYP1A2GRM5ALDH1A1CHRM2OPRM1 | |
| SCHEMBL13833230 | 0.77 | DDB1 (0.37) | CYP1A2GRM5ALDH1A1CHRM2OPRM1 | |
| SCHEMBL15913993 | 0.77 | DDB1 (0.37) | CYP1A2GRM5ALDH1A1CHRM2OPRM1 | |
| SCHEMBL15913532 | 0.67 | PIM1 (0.75) | PIM1PIM2 | |
| SCHEMBL15913533 | 0.67 | PIM1 (0.75) | PIM1PIM2 | |
| SCHEMBL15913534 | 0.67 | PIM1 (0.75) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | CYP1A2 627/4885GRM5 3876/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.